Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SB 01 - Spine Biopharma

Next Previous
Drug Profile

SB 01 - Spine Biopharma

Alternative Names: P2K; Peniel 2K; Peniel-2000; Remedisc; SB-01; YH-14618

Latest Information Update: 01 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ensol Biosciences
  • Developer Spine Biopharma; Yuhan
  • Class Peptides
  • Mechanism of Action Nerve growth factor inhibitors; Transforming growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Intervertebral disc degeneration

Most Recent Events

  • 25 Sep 2024 Spine BioPharma completes enrolment in the phase III (MODEL) trial for Intervertebral disc degeneration in USA (Intra-articular)
  • 10 Jul 2024 Spine Biopharma signs an agreement with Ensol BioSciences to expand the indications of SB 01 for injection
  • 22 Jul 2022 No development reported - Phase-II for Intervertebral disc degeneration in South Korea (Intra-articular)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top